227 related articles for article (PubMed ID: 23074172)
1. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.
Cittelly DM; Dimitrova I; Howe EN; Cochrane DR; Jean A; Spoelstra NS; Post MD; Lu X; Broaddus RR; Spillman MA; Richer JK
Mol Cancer Ther; 2012 Dec; 11(12):2556-65. PubMed ID: 23074172
[TBL] [Abstract][Full Text] [Related]
2. MiR-200c and HuR in ovarian cancer.
Prislei S; Martinelli E; Mariani M; Raspaglio G; Sieber S; Ferrandina G; Shahabi S; Scambia G; Ferlini C
BMC Cancer; 2013 Feb; 13():72. PubMed ID: 23394580
[TBL] [Abstract][Full Text] [Related]
3. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
4. Targets of miR-200c mediate suppression of cell motility and anoikis resistance.
Howe EN; Cochrane DR; Richer JK
Breast Cancer Res; 2011 Apr; 13(2):R45. PubMed ID: 21501518
[TBL] [Abstract][Full Text] [Related]
5. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
Zhu X; Li Y; Xie C; Yin X; Liu Y; Cao Y; Fang Y; Lin X; Xu Y; Xu W; Shen H; Wen J
Int J Cancer; 2014 Sep; 135(6):1286-96. PubMed ID: 24510775
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis.
Mak CS; Yung MM; Hui LM; Leung LL; Liang R; Chen K; Liu SS; Qin Y; Leung TH; Lee KF; Chan KK; Ngan HY; Chan DW
Mol Cancer; 2017 Jan; 16(1):11. PubMed ID: 28095864
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell.
Liu J; Meng T; Yuan M; Wen L; Cheng B; Liu N; Huang X; Hong Y; Yuan H; Hu F
Int J Nanomedicine; 2016; 11():6713-6725. PubMed ID: 28003747
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents.
Cochrane DR; Spoelstra NS; Howe EN; Nordeen SK; Richer JK
Mol Cancer Ther; 2009 May; 8(5):1055-66. PubMed ID: 19435871
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
10. Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers.
Cochrane DR; Howe EN; Spoelstra NS; Richer JK
J Oncol; 2010; 2010():821717. PubMed ID: 20049172
[TBL] [Abstract][Full Text] [Related]
11. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles.
Liu Q; Li RT; Qian HQ; Wei J; Xie L; Shen J; Yang M; Qian XP; Yu LX; Jiang XQ; Liu BR
Biomaterials; 2013 Sep; 34(29):7191-203. PubMed ID: 23806972
[TBL] [Abstract][Full Text] [Related]
13. Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
Kim YW; Kim EY; Jeon D; Liu JL; Kim HS; Choi JW; Ahn WS
Drug Des Devel Ther; 2014; 8():293-314. PubMed ID: 24591819
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Wu DD; Li XS; Meng XN; Yan J; Zong ZH
Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
[TBL] [Abstract][Full Text] [Related]
15. Coordinated regulation of β-tubulin isotypes and epithelial-to-mesenchymal transition protein ZEB1 in breast cancer cells.
Lobert S; Graichen ME; Morris K
Biochemistry; 2013 Aug; 52(32):5482-90. PubMed ID: 23869586
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-200c and microRNA-31 regulate proliferation, colony formation, migration and invasion in serous ovarian cancer.
Ibrahim FF; Jamal R; Syafruddin SE; Ab Mutalib NS; Saidin S; MdZin RR; Hossain Mollah MM; Mokhtar NM
J Ovarian Res; 2015 Aug; 8():56. PubMed ID: 26260454
[TBL] [Abstract][Full Text] [Related]
17. Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel.
Chen N; Chon HS; Xiong Y; Marchion DC; Judson PL; Hakam A; Gonzalez-Bosquet J; Permuth-Wey J; Wenham RM; Apte SM; Cheng JQ; Sellers TA; Lancaster JM
Oncol Rep; 2014 Jan; 31(1):376-83. PubMed ID: 24220856
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.
Gao S; Zhao X; Lin B; Hu Z; Yan L; Gao J
Tumour Biol; 2012 Oct; 33(5):1759-65. PubMed ID: 22684772
[TBL] [Abstract][Full Text] [Related]
19. Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
Duran GE; Wang YC; Moisan F; Francisco EB; Sikic BI
Br J Cancer; 2017 May; 116(10):1318-1328. PubMed ID: 28399108
[TBL] [Abstract][Full Text] [Related]
20. miR-450a Acts as a Tumor Suppressor in Ovarian Cancer by Regulating Energy Metabolism.
Muys BR; Sousa JF; Plaça JR; de Araújo LF; Sarshad AA; Anastasakis DG; Wang X; Li XL; de Molfetta GA; Ramão A; Lal A; Vidal DO; Hafner M; Silva WA
Cancer Res; 2019 Jul; 79(13):3294-3305. PubMed ID: 31101765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
